8-K: Enhabit Reports Mixed Q4 Results, Issues Cautious 2025 Guidance

Enhabit reports a net loss for Q4 2024 but shows growth in hospice and non-Medicare home health segments, issuing full-year 2025 guidance with revenue between $1.05 billion and $1.08 billion.

Summary

• Enhabit, Inc. reported its Q4 2024 results, showing a net service revenue of $258.2 million.
• The company experienced a net loss attributable to Enhabit, Inc. of $46.0 million, with a loss per share of $0.92.
• Adjusted EBITDA for the quarter was $25.1 million, with adjusted earnings per share of $0.04.
• Home health non-Medicare admissions increased by 10.7%, leading to a total admissions growth of 1.8% year over year.
• Hospice average daily census increased by 8.6% year over year, with admissions up by 6.5%.
• Hospice net service revenue increased by 13.1%, and Adjusted EBITDA increased by 13.7% year over year.
• The company reduced bank debt by $10 million in Q4, bringing the total 2024 debt reduction to $40 million.
• Enhabit opened three hospice de novo locations in Q4, totaling one home health and five hospice de novo locations for 2024.
• For 2025, Enhabit anticipates net service revenue between $1,050 and $1,080 million, adjusted EBITDA between $101 and $107 million, and adjusted EPS between $0.41 and $0.51.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positives such as growth in hospice and non-Medicare home health, debt reduction, and cost control, the net loss and decreased home health revenue temper the overall outlook. The guidance for 2025 is cautiously optimistic.

Positives

• Home health non-Medicare admissions increased by 10.7%, driving total admissions growth.
• Hospice average daily census increased by 8.6% year over year, indicating strong growth in that segment.
• Hospice net service revenue increased by 13.1%, and Adjusted EBITDA increased by 13.7% year over year, showcasing the segment's profitability.
• The company reduced bank debt by $40 million in 2024, strengthening its financial position.
• Home office G&A expenses decreased approximately 12% due to cost control initiatives.
• 48% of home health non-Medicare visits are now in payer innovation contracts at improved rates.
• 30-day home health hospital readmission rate 20.0% better than national average.

Negatives

• The company reported a net loss attributable to Enhabit, Inc. of $46.0 million for Q4 2024.
• Home health net service revenue decreased by 4.3% compared to the previous year.
• Adjusted diluted EPS decreased from $0.06 to $0.04 year over year.
• Impairment of goodwill of $53.8 million was recorded in Q4 2024.
• Medicare admissions decreased 7.8% year over year.
• Medicare average daily census decreased 11.6% year over year.

Risks

• The company's ability to execute its strategic plans is a key risk.
• Regulatory and other developments impacting the markets for its services could affect performance.
• Changes in reimbursement rates may impact revenue.
• General economic conditions could influence demand for services.
• The company faces risks related to attracting and retaining key management personnel and healthcare professionals.
• Potential disruptions or breaches of information systems could negatively impact operations.
• The outcome of litigation could have financial implications.
• Quality performance and ratings can affect the company's reputation and business.
• The ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures is crucial.
• Controlling costs, particularly labor and employee benefit costs, is essential for profitability.

Future Outlook

Enhabit provides full-year 2025 guidance, projecting net service revenue between $1,050 and $1,080 million, adjusted EBITDA between $101 and $107 million, and adjusted EPS between $0.41 and $0.51.

Management Comments

• Barb Jacobsmeyer, president and chief executive officer of Enhabit, stated that Enhabit is exiting 2024 having executed specific strategies that set the company up for long-term growth in both home health and hospice segments.
• She noted the stabilization of Medicare census in the home health segment and the completion of a large national contract renegotiation.
• She also highlighted the hospice segment's growth in average daily census since January 2024 due to the maturing case management model.

Industry Context

Enhabit operates in the home health and hospice care industry, which is influenced by factors such as regulatory changes, reimbursement rates, and demographic trends. The company's focus on payer innovation and cost control aligns with industry trends aimed at improving efficiency and quality of care.

Comparison to Industry Standards

• Enhabit's 30-day home health hospital readmission rate is 20.0% better than the national average, indicating superior performance in patient care compared to industry benchmarks.
• The company's Quality of Patient Care (QoPC) Star Rating is 3.1, slightly above the national average of 3.0.
• Enhabit's Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Patient Survey Star Rating is 4.1, also above the national average of 3.9.
• Hospice visits in the last days of life are at 67.1% compared to a national average of 47.4%.

Stakeholder Impact

• Shareholders will be concerned about the net loss but may be encouraged by the growth in certain segments and the 2025 guidance.
• Employees may be affected by cost control initiatives and restructuring activities.
• Patients should benefit from the company's focus on quality and patient experience.
• Payers will be interested in the company's payer innovation strategy and value-based performance.
• Creditors will be reassured by the company's debt reduction efforts.

Next Steps

• The company will host an investor conference call on March 6, 2025, to discuss the Q4 2024 results.
• Enhabit will focus on executing its 2025 priorities, including home health census growth, payer mix optimization, hospice average daily census growth, and G&A expense management.
• The company plans to continue de-leveraging the balance sheet and opening de novo locations in strategic markets.

Key Dates